Mission Produce signals cash flow pivot with $40m CapEx plan and leadership handover to John Pawlowski
Discover how Mission Produce’s CapEx reset to ~$40M and CEO succession signal a shift to cash flow and global expansion strategy—find out what’s next!
Meiji Seika Pharma partners with MBC BioLabs to tap early-stage biotech innovation in the U.S.
Meiji Seika Pharma partners with MBC BioLabs to tap early-stage U.S. biotech startups. Find out what this means for its global drug discovery strategy.
ANZ fined A$250m for systemic misconduct across bond markets and retail banking
ANZ has been hit with a record A$250M fine for systemic misconduct. Find out how this changes banking regulation and investor risk in Australia.
Can Nike rebuild 10% margins by 2026? Inside the “Sport 2025” restructuring strategy
Nike has launched a full reset in fiscal 2025, aiming to restore double-digit EBIT margins by 2026. Find out what its “Sport 2025” strategy means for investors.
Coursera (NYSE: COUR) and Udemy (NASDAQ: UDMY) to combine as skills race accelerates
Coursera is merging with Udemy in a $2.5B deal to reshape AI-driven learning. Find out what this means for skills, platforms, and enterprise training.
Port Talbot support fund hits £122m as UK doubles down on Tata Steel transition
The UK Government added £22 million to support Port Talbot steelworkers and businesses during Tata Steel’s green shift. Find out what this means for the region.
Why Denta Water and Infra (NSE: DENTA) just became a serious player in Karnataka’s urban sanitation push
Denta Water and Infra Solutions secures ₹106 crore in Karnataka infra contracts across seven districts. Learn what this means for execution, DBOT strategy, and investors.
Aspire Mining (ASX: AKM) locks in $70m EPC deal for Ovoot project infrastructure, targets first coal by Q4 2027
Aspire Mining secures US$69.9M EPC deal for its Mongolian coal project. Find out how this de-risks development and sets the stage for first exports by 2027.
Can GSK’s Exdensur transform asthma biologics with just two doses per year?
GSK’s Exdensur is now FDA approved as the first biannual biologic for severe asthma. Explore what this means for rivals, payers, and global strategy.
Bristol Myers Squibb signs $1.1bn multi-specific antibody discovery deal with Harbour BioMed
Harbour BioMed signed a $1.125B discovery deal with Bristol Myers Squibb to co-develop multi-specific antibodies. Read the full strategic breakdown now.